IDEXX Laboratories, Inc. vs Lockheed Martin Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B), while Lockheed Martin Corporation trades at $605.85 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 3× IDEXX Laboratories, Inc.'s market cap, and Lockheed Martin Corporation pays a 2.31% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LMT | |
|---|---|---|
Market Cap | $46.22B | $137.96B |
Sector | Health | Industrials |
52-Week High | $766.68 | $676.70 |
52-Week Low | $526.44 | $431.56 |
Enterprise Value | $47.12B | $154.71B |
Dividend Yield | — | 2.31% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Lockheed Martin (LMT) trades at $601.99, down 0.19% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a record $230.4 billion backlog (Seeking Alpha, 2026-08-04), revenue growth to $75.05 billion in 2025, and a net income margin of 8.16%. Recent news highlights major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, 2026-08-11), supporting long-term growth.
The outlook for LMT is positive, driven by expanding defense budgets and execution on its backlog, though risks include earnings misses and debt levels. Analysts project a consensus price target of $608, with 57% recommending buy. The stock's valuation metrics, such as a P/E of 22.04, appear reasonable given growth prospects, but investors should monitor contract execution and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →